AU2013202441A1 — Controlled release formulations comprising uncoated discrete unit(s) and an extended release matrix
Assigned to Alphapharm Pty Ltd · Expires 2013-05-02 · 13y expired
What this patent protects
- 34 Abstract A controlled-release formulation comprising one or more distinct and discrete units located in physical juxtaposition to enable administration to a patient in 5 need of treatment in a single dose, characterised in that the or each unit comprise(s): (i) a unit dose o…
USPTO Abstract
- 34 Abstract A controlled-release formulation comprising one or more distinct and discrete units located in physical juxtaposition to enable administration to a patient in 5 need of treatment in a single dose, characterised in that the or each unit comprise(s): (i) a unit dose of an active pharmaceutical ingredient or pharmaceutically acceptable salt thereof; 10 (ii) one or more extended-release agent(s); and, optionally, (iii) one or more pharmaceutically acceptable excipients, wherein the sum of the unit dose(s) constitutes a 15 pharmaceutically effective amount of the active pharmaceutical ingredient. 4213461_1 (GHMatters) P75754.AU.3
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.